Alzheimer's disease

News

End looms for Cassava's simufilam in Alzheimer's disease

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end

News

Eisai dials back forecasts for Alzheimer's drug Leqembi

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish.

R&D

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.

News

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on

News

Lexeo shares dip on early data with Alzheimer's gene therapy

Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.

News

Lilly touts new Kisunla regimen that reduces side effects

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions f

End looms for Cassava's simufilam in Alzheimer's disease

Eisai dials back forecasts for Alzheimer's drug Leqembi

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Lexeo shares dip on early data with Alzheimer's gene therapy

Lilly touts new Kisunla regimen that reduces side effects

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

Alzheimer's disease

Editor's Picks